- A comparison of its previous movement and predicted movement is provided here-in-below:
- The last trend started from 2nd week of October, 2018 which lasted till March, 2019; in which the stock gave as good as 66% return
- Note that from Oct to Jan, the stock was consolidating between the 50% and 61.8% retracement level.
- The current trend begins from Feb...
IPCA DAY CHART IS SHOWING A LOT OF ACCUMULATION WITH A RANGE FROM 920-1000.
AS INDICATED IN ONE OF THE PREVIOUS POST, PRICE SHOT UP TO 1000 LVLS AND THE PROFITS WERE BOOKED.
A PIN BAR SORT OF FORMATION IS OBSERVED TODAY.
THIS TIME IT MAY SHOOT UP BEYOND 1000, AS THE FUTURE CLOUDS ARE BULLISH.
ANOTHER PHARMA SCRIP COMING ONTO THE SCREEN FOR BUY.
LET THE SHARE TRADE ABOVE THE RESISTANCE LEVEL, THEN ONE MAY ENTER FOR TARGET OF 1046 IN THE COMING DAYS.
IF ANY CORRECTIONS PLEASE CORRECT ME. I LOVE CHARTING AND TRYING TO LEARN MARKET. IPCA LAB FORMS A FLAG BREAKOUT. OVERALL IN BULLISH TREND.GOOD MID TERM STOCK.
- Excellent stock for entering short
- Every time the stock hits its the trend line it bounces back to its 50 DMA which lies somewhere around 770 levels
- Note dropping volume, indicating that sellers are taking the toll
- RSI is just hovering near to oversold zones
- MACD is indicating loss of momentum
-
Disclaimer: This idea has been posted strictly for educational purposes only and any investment call shall be taken post proper due diligence and consultation of a certified Financial Advisor
IPCA LAB has been bouncing off the multiyear trendline. currently testing it again after a huge arc.
Awaiting a breakout/reversal on account of Results today.
V can see trgts of 800 900 in long term view
its made DOUBLE BOTTOM in monthly chart
wit sl 625
This Free Educational, IT has been created ONLY for EDUCATIONAL PURPOSES. It DOES NOT provide any ADVICE or RECOMMENDATION. The view DOES NOT provide any STOCK MARKET TIPS. All the posts are only for INFORMATION purpose and are purely PERSONAL VIEWS and OPINIONS...
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs). It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax. Its 3c division focuses on cardiovascular and anti-diabetic markets. Its 3d division is focused on cardio-diabetic market. The Company's activa division serves the rheumatology market. Its altus division caters to the needs of intensivists, both surgical and non-surgical. Its Bionova division's focus area is dermatology. Its dynamix division focuses on cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory sectors. It hycare division caters to the needs of cardiologists and diabetologists. Its divisions also include innova, intima, pain management, pharma and uro sciences.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
IPCALAB
